Literature DB >> 23216585

Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.

Giancarlo Zito1, Renato Polimanti, Valentina Panetta, Mariacarla Ventriglia, Carlo Salustri, Maria Cristina Siotto, Filomena Moffa, Claudia Altamura, Fabrizio Vernieri, Domenico Lupoi, Emanuele Cassetta, Paolo M Rossini, Rosanna Squitti.   

Abstract

Different factors interact to develop neurodegeneration in patients with dementia and other neurodegenerative disorders. Oxidative stress and the ε4 allele of apolipoprotein E (ApoE) are associated with significant alteration in lipid metabolism, in turn connected to a variety of neurodegenerative diseases and aging. Thus, a better understanding of the pathogenetic pathways associated with lipid dyshomeostasis may elucidate the causes of neurodegenerative processes. To address this issue, we evaluated the effects of antioxidant status and APOE genotype on neurodegeneration in patients with dementia of the Alzheimer type (AD), with vascular dementia (VaD), and in elderly healthy controls. Eighty-two AD, 42 VaD patients, and 26 healthy controls were recruited and underwent medial temporal lobe atrophy (MTA) assessment, white matter hyperintensities rating (WMH), serum total antioxidant status assaying (TAS), and APOE genotyping. A logistic regression algorithm applied to our data revealed that a 0.01 mmol/L decrease of TAS concentration increased the probability of MTA by 24% (p=0.038) and that carriers of the APOE ε4 allele showed higher WMH scores (p=0.018), confirming that small variations in antioxidant systems homeostasis are associated with relevant modifications of disease risk. Furthermore, in individuals with analogous TAS values, the presence of the ε4 allele increased the predicted probability of having MTA. These outcomes further sustain the interaction of oxidative stress and APOE genotype to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23216585      PMCID: PMC3582293          DOI: 10.1089/rej.2012.1383

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  53 in total

1.  Total antioxidant status in plasma and body fluids.

Authors:  C Rice-Evans; N J Miller
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

2.  Capillary CAA and perivascular Aβ-deposition: two distinct features of Alzheimer's disease pathology.

Authors:  Johannes Attems; Haruyasu Yamaguchi; Takaomi C Saido; Dietmar Rudolf Thal
Journal:  J Neurol Sci       Date:  2010-09-17       Impact factor: 3.181

3.  Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains.

Authors:  John Provias; Brian Jeynes
Journal:  Curr Alzheimer Res       Date:  2011-03       Impact factor: 3.498

Review 4.  Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.

Authors:  Zsolt Radak; Zhongfu Zhao; Sataro Goto; Erika Koltai
Journal:  Mol Aspects Med       Date:  2011-10-15

Review 5.  Vascular cognitive impairment: current concepts and clinical developments.

Authors:  Paige Moorhouse; Kenneth Rockwood
Journal:  Lancet Neurol       Date:  2008-03       Impact factor: 44.182

6.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

7.  Ceruloplasmin/Transferrin system is related to clinical status in acute stroke.

Authors:  Claudia Altamura; Rosanna Squitti; Patrizio Pasqualetti; Chiara Gaudino; Paola Palazzo; Francesco Tibuzzi; Domenico Lupoi; Maurizio Cortesi; Paolo Maria Rossini; Fabrizio Vernieri
Journal:  Stroke       Date:  2009-02-19       Impact factor: 7.914

8.  Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease.

Authors:  Hadi Kharrazi; Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Mahdi Aminian; Tayebeh Pourmotabbed
Journal:  Clin Biochem       Date:  2008-05-15       Impact factor: 3.281

Review 9.  Apolipoprotein E, an important player in longevity and age-related diseases.

Authors:  Lisa S Ang; Rani P Cruz; Alon Hendel; David J Granville
Journal:  Exp Gerontol       Date:  2008-04-04       Impact factor: 4.032

10.  Total antioxidant status correlates with cognitive impairment in patients with recurrent depressive disorder.

Authors:  Monika Talarowska; Piotr Gałecki; Michael Maes; Kinga Bobińska; Edward Kowalczyk
Journal:  Neurochem Res       Date:  2012-05-05       Impact factor: 3.996

View more
  5 in total

1.  Apolipoprotein E ε4/4 genotype limits response to dietary induction of hyperhomocysteinemia and resulting inflammatory signaling.

Authors:  Charles E Seaks; Erica M Weekman; Tiffany L Sudduth; Kevin Xie; Brandi Wasek; David W Fardo; Lance A Johnson; Teodoro Bottiglieri; Donna M Wilcock
Journal:  J Cereb Blood Flow Metab       Date:  2022-01-13       Impact factor: 6.960

Review 2.  The role of APOE in cerebrovascular dysfunction.

Authors:  Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu
Journal:  Acta Neuropathol       Date:  2016-02-16       Impact factor: 17.088

3.  Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies.

Authors:  Caitlin S Latimer; C Dirk Keene; Margaret E Flanagan; Laura S Hemmy; Kelvin O Lim; Lon R White; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.148

4.  Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men.

Authors:  Cheng Ma; Jin Li; Zhijun Bao; Qingwei Ruan; Zhuowei Yu
Journal:  Biomed Res Int       Date:  2015-11-23       Impact factor: 3.411

Review 5.  Modeling Alzheimer's disease with non-transgenic rat models.

Authors:  Laurent Lecanu; Vassilios Papadopoulos
Journal:  Alzheimers Res Ther       Date:  2013-05-01       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.